Patients treated with PD-1 inhibitors were found to have a slightly higher rate of irAEs (16% vs. 11%, P = 0.07) and pneumonitis (4% vs. 2%, P = 0.01) compared to patients who received PD-L1 inhibitors (25). This evidence concerns the gene PDCD1 and pneumonitis.